Siro ClinPharm and ACT team up on oncology

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical trial

Indian CRO Siro ClinPharm is teaming up with New Jersey based pharma services firm Advanced Clinical Trial Solutions (ACT) to strengthen its position in the US cancer trial sector.

The partnership, financial terms of which have not been released, will add ACT’s clinical development and patient recruitment offerings for oncology drug trials to Siro’s existing portfolio of services.

In return, ACT’s US customer base will have access to Siro’s extensive network of Indian and European data management, patient recruitment, biostatistics and distribution services.

Siro’s US president, Patricia Terek, reiterated the projects’ core focus, explaining that the deal “will help meet the growing needs of our oncology customers to have access to operational capabilities in North America.”

Siro, which is India’s largest integrated clinical trials organisation, entered the US market in July 2007 through its acquisition of contract research organisation (CRO) Global Client Partners.

The firm also has operations in Germany, Greece, Estonia and Israel, that it bought as part of its takeover of Offenbach-based firm Omega Mediation in 2008.

Siro to Invest in India?

While the ACT partnership clearly shows the value Siro places on the US market, recent comments by shareholder 3i India suggest that the Mumbai group plans to further strengthen its position in its home territory.

3i India’s Mahesh Chhabria told Livemint​ that: “ We are currently looking at several proposals for comparatively large investments in the country’s pharmaceuticals, medical devices manufacturing, and health care and laboratory services industries, including large and medium hospital groups​.”

Chhabria explained that two of the options under consideration are acquisitions by Siro in India, but said that no move would be made until the integration of Omega is completed later this year.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more